--- title: "Weekly Recap | Elevance Health -8.19%, heavy-volume sell-off" type: "News" locale: "en" url: "https://longbridge.com/en/news/306356566.md" description: "Elevance Health finished the week down 8.19% at $394.48, slightly outperforming the S&P 500’s 8.61% drop by about 0.42 percentage points. Trading was heavy, with the weekly range spanning 14.66%. The stock opened Monday at $438.27 and touched $447.42 before rolling over; Wednesday saw it break below $400 on higher volume, Thursday marked the weekly low at $383.17, and Friday stabilised at $394.48. Average daily volume of roughly 2.03m shares ran about 68% above the 60-day median." datetime: "2026-11-21T06:29:09.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/306356566.md) - [en](https://longbridge.com/en/news/306356566.md) - [zh-HK](https://longbridge.com/zh-HK/news/306356566.md) generator: "portal-rs" --- # Weekly Recap | Elevance Health -8.19%, heavy-volume sell-off ## The Week Elevance Health finished the week down 8.19% at $394.48, slightly outperforming the S&P 500’s 8.61% drop by about 0.42 percentage points. Trading was heavy, with the weekly range spanning 14.66%. The stock opened Monday at $438.27 and touched $447.42 before rolling over; Wednesday saw it break below $400 on higher volume, Thursday marked the weekly low at $383.17, and Friday stabilised at $394.48. Average daily volume of roughly 2.03m shares ran about 68% above the 60-day median. ## Key Events Managed-care names faced broad pressure this week. On 17 November, a proposed rule to curb fraud surfaced after the close, sending health insurers lower. CMS audit proposals and Medicare-for-All concerns then kept the sector under pressure, with US health insurers falling for three straight days through Friday. Elevance was caught in the sell-off, down nearly 4% intraday on Wednesday and more than 4% on Friday. Still, the stock outperformed peers on several sessions, and talk of a Medicaid margin recovery plan circulated during the week. Director Ramiro G. Peru reported buying $383,860 in common shares on Friday, one of the few company-specific positives in an otherwise regulatory-driven week. ## Analyst Ratings Across 22 covering brokers, 13 rate the stock buy, 3 rate it overweight, and 6 rate it hold, with no sell or underweight ratings. The consensus rating is buy, and the consensus target of $482.38 sits roughly 22.3% above spot. Individual targets range from $406 to $523, pointing to a wide spread. Within the managed-care industry of nine names, Elevance ranks third on analyst ratings. ## The Week Ahead On the macro front, 24 November brings FHFA house prices, Case Shiller 20-city home prices, consumer confidence (prior 91.7, estimate 92.5), and the Richmond Fed composite index. Company-specific catalysts are further out: Elevance reports FY2026 results before the open on 27 January 2027, with consensus estimates at EPS of $22.4279 and revenue of $198.8bn. ## In Short The week paired a steep sell-off with an analyst community that still largely rates the stock buy and carries a consensus target above spot, leaving a tension between price action and conviction. Fresh daily fund flows also showed net buying from smaller lots against net selling from large lots, highlighting disagreement within the tape. The key follow-through now is how the regulatory proposals evolve and whether next week’s macro prints shift sentiment in the managed-care group. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [ELV.US](https://longbridge.com/en/quote/ELV.US.md) ## Related News & Research - [What Elevance Health (ELV)'s Medicaid Margin Recovery Plan Means For Shareholders](https://longbridge.com/en/news/305922488.md) - [What Elevance Health Holders Got Right](https://longbridge.com/en/news/306380588.md) - [Elevance Health Director Ramiro G. Peru Reports Acquisition of $383,860 in Common Shares](https://longbridge.com/en/news/306285611.md) - [Elevance Health (ELV) Raises Earnings Outlook Following Fair Value Gap Comes Into Focus](https://longbridge.com/en/news/305294781.md) - [This Elevance Health Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday](https://longbridge.com/en/news/306003889.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**